REMARKS

Claims 1-5, 7, 9-13, 15 and 17-51 presently appear in this case. No claims have yet been examined on the merits in this continuation application. The present amendments are being made in order to place the case into better condition for examination. The final rejection of July 19, 2004, in the parent case, application no. 09/893,348, has now been carefully studied. Prompt consideration and allowance are hereby respectfully urged.

Briefly, the present invention relates to technology developed in the laboratory of the present inventors, which is now known in the art as autoimmune neuroprotection. been discovered that secondary neuronal degeneration caused by the neurodegenerative effects of an injury, disease, disorder or condition can be reduced if steps are taken to cause T cells activated against an NS-specific antigen which, in its native state, is present at the site of secondary neuronal degeneration, to accumulate at the site of neuronal degeneration. The mere presence of these activated T cells at the site of secondary neurodegeneration causes a cytokine response that has a significant effect in reducing the secondary neuronal degeneration. The preferred method of causing the T cells to accumulate at the site of secondary neurodegeneration is either to administer T cells activated against an NS-specific antigen, or an immunogenic or cryptic epitope thereof, or to administer the NS-specific antigen, or the immunogenic or cryptic epitope thereof, itself in such a

way as to cause a T cell response such that T cells become activated against the NS-specific antigen.

In a review of the present application as filed it has been noted that the pages of declaration filed with this case, which were indicated as being copies from parent application no. 09/893,348, are incorrect copies, in part. Attached hereto is a correct copy of the declarations as originally filed in parent application 09/893,348. The attached copies were downloaded from the Image File Wrapper of the file for 09/893,348, so it can be verified that these are, indeed, copies of the actual papers filed in that case. Please substitute the attached copy of the declarations from the parent case for the pages of declaration filed on March 29, 2004.

It has further been noted that the papers as originally filed did not claim benefit of the priority of Israeli application 124550, filed May 19, 1998. Such priority is hereby claimed. A certified copy of said Israeli application was filed as a priority document in grandparent application 09/314,161 on May 19, 1999. The attached Application Data Sheet includes this claim for priority.

The interview among Examiners Bunner and Kunz and the undersigned attorney on July 14, 2004, is hereby gratefully acknowledged. Prior to the interview, a chart was forwarded to the examiners showing evidence establishing the broad range of proven activity for various indications and various peptides and T cells. A slightly revised copy of this

chart is attached hereto. At the interview, the enablement issues were discussed in light of this evidence. Furthermore, the examiners were forwarded a manuscript by two of the present inventors entitled "A Common Vaccine for Fighting Off Neurodegenerative Disorders: Recharging Immunity for Homeostasis." This has now been published at Trends in Pharmacological Sciences, 25:407-12 (2004), a copy of which is attached hereto. This manuscript explains that the self-perpetuating spread of damage that follows acute injury or occurs independently of primary risk factors in any chronic neurodegenerative disorder is commonly viewed as secondary degeneration, and that the mechanisms that underlie the secondary degeneration are the same, regardless of whether they are secondary to the primary insult of an injury or the primary risk factors of a chronic neurodegenerative disorder.

As a result of the interview, the examiners agreed to reconsider the restriction requirement, particularly if additional evidence could be provided establishing that the mechanisms that underlie the secondary degeneration are the same for secondary degeneration following acute injury, as well as chronic neurodegenerative diseases. However, the examiners stated that the independent claims would have to specify the manner of causing the T cells to accumulate at the site of neurodegeneration, such as by specifying the two ways of doing so alternatively, i.e., administering NS-specific antigen or administering T cells activated against NS-specific antigen. Furthermore, the examiners stated that the

enablement objection would be reconsidered if the claims made very clear that the method was for reducing secondary neuronal degeneration that follows neuronal damage caused by an injury or disease.

The arguments presented at the interview will be repeated hereinbelow in the discussion of the various rejections.

In the final rejection of March 4, 2004, the examiner indicated that claims 46-48, 51-52, 54-56 and 59-60 were withdrawn from consideration in view of the restriction requirement. However, as pointed out in the interview discussed above as well as the interview of June 26, 2003, in the parent case, the same mediators are involved in secondary neuronal degeneration, regardless of whether the primary insult is an acute injury or the chronic degeneration of a disease. As evidence of this conclusion, the examiner's attention is invited to the attached manuscript of Schwartz and Kipnis, as well as the following two attached references:

- (1) FRIEDLANDER, R.M. "Apoptosis and Caspases in Neurodegenerative Diseases" \underline{N} Engl J Med, 348:1365-75 (2000)
- (2) VAJDA, F.J.E. "Neuroprotection and neurodegenerative disease" <u>J Clin Neurosci</u>, 9:4-8 (2002)

Friedlander is a review that very clearly includes stroke, brain trauma, spinal cord injury, ALS, Parkinson's disease, etc., in the same category of neurodegenerative diseases. Vajda is another review that describes pathological pathways in five different neurodegenerative diseases. It is

believed that these reviews confirm the statements in the Schwartz and Kipnis manuscript that the same factors, i.e, the same mediators, are involved in secondary neuronal degeneration, regardless of whether the primary insult is an acute injury or the chronic degeneration of a disease.

Furthermore, as will be discussed below, it is believed that the objections to the generic claims in this case will be overcome by the present amendment specifying two alternative ways of causing the T cells to accumulate at the site of secondary neurodegeneration. As it is believed that these generic claims will now be considered to be allowable, withdrawal of the restriction requirement would be in order with respect to the species that fall within this genus.

Accordingly, reconsideration and withdrawal of the restriction requirement are again respectfully urged.

In the final rejection, the examiner stated that the declaration was defective because of non-initialled or non-dated alterations. The examiner stated that no Application Data Sheet was found attached to the response in the parent case.

Attached hereto is an Application Data Sheet submitting the correct information as to the residence and post office addresses of all of the inventors, which supersedes the data in the originally filed declaration.

Accordingly, it is submitted that in view of this Application Data Sheet, it is no longer necessary to have the declaration re-executed.

In the final rejection in the parent case, the examiner objected to the specification because the status of the patent applications listed in the first paragraph of the specification, as well as at pages 5 and 58, needed to be updated.

The specification has now been amended to update the status of all of these applications. As all of them are now abandoned, this objection can now be withdrawn.

The examiner has maintained the double patenting rejection over the claims of application serial no. 09/218,277. However, as this application has now been abandoned, this double patenting rejection has now become obviated.

Claims 45 and 53 were provisionally rejected under the judicially created doctrine of obviousness type double patenting as being unpatentable over claim 38 of copending application no. 09/314,161. This rejection is respectfully traversed.

Application 09/314,161 has now also been abandoned, thus obviating this obviousness type double patenting rejection.

In the final rejection in the parent case, claims 45, 49-50, 53 and 57-58 were rejected under 35 U.S.C. §112, first paragraph, because the specification, while being enabling for a method for promoting recovery from spinal cord injury comprising subcutaneously administering to an individual in need thereof a composition comprising a peptide

derived from Nogo-A, does not reasonably provide enablement for a method for reducing neuronal degeneration caused by the neurodegenerative effects of disease, or for reducing secondary neuronal degeneration that follows the primary neuronal damage of an injury in the central or peripheral nervous system of an individual in need thereof, comprising causing T cells activated against an NS-specific antigen to accumulate at the site of neuronal degeneration. The examiner also stated that the claims also recite that the individual in need is one suffering from an injury that has caused primary neuronal damage. The examiner states that the specification does not enable any person skilled in the art to which it pertains to make or use the invention commensurate in scope with these claims. This rejection is respectfully traversed.

As discussed in the above-mentioned interview, the present amendment now clarifies that it is only directed to reducing secondary neuronal degeneration that follows neuronal damage caused by an injury, disease, condition or disorder. In this regard, reference is made to the present specification at page 8, lines 1-6, which refers to the protection of nervous system tissue "from secondary degeneration which may follow damage caused by injury or disease of the CNS or PNS." This new language, which is supported by the specification as indicated above, now makes clear that the claims are directed only to a method of reducing secondary neuronal degeneration. Furthermore, the Schwartz and Kipnis manuscript and the Friedlander and Vajda publications, discussed above and

attached hereto, establish that the same factors, i.e., the same mediators, are involved in secondary neuronal degeneration, regardless of whether the primary insult is an acute injury or the chronic degeneration of a disease. Accordingly, the evidence of record that the present invention is operative to ameliorate the secondary neuronal degeneration following crush-injured CNS nerves, as well as the other evidence of record about the treatment of secondary neurodegenerative effects caused by intraocular pressure (see Bakalash et al, Invest. Opthamal. Vis. Sci. 44:3374-3381 (2003), copy attached) would lead one of ordinary skill in the art reading the present specification to understand that such secondary neuronal degeneration can be treated, regardless of whether it is secondary to various acute injuries or various chronic neurodegenerative diseases, disorders or conditions. Note also that the examples in the present application establish that both T cells activated against an NS-specific antigen and the antigen itself are active in reducing the secondary neurodegenerative effects following optic crush injury and following spinal cord injury. The attached chart also gives references to papers from the laboratory of the present inventors relating to effectiveness of other NSspecific antigens.

Furthermore, it should be understood that applicant's copending application, 09/765,644 (now issued as patent no. 6,844,314 with claims very similar to those herein), is directed to treating the same indications as in

the present invention, except that the T cells that are caused to accumulate at the site of secondary neuronal degeneration are T cells activated by Copolymer 1, rather than an NSspecific antigen. It was discovered that Copolymer 1 acts in a manner similar to NS-specific antigens for the purpose of autoimmune neuroprotection. The laboratory of the present inventor has done many additional tests relating to other indications using Copolymer 1 rather than an NS-specific antigen which, in its native state, is present at the site of secondary neuronal degeneration. As explained by Prof. Schwartz in her presentation at the interview on June 26, 2003, the experimental evidence obtained with Copolymer 1 and T cells activated against Copolymer 1 prove the concept of the present invention in other indications, and thus would lead one of ordinary skill in the art to believe that if an NSspecific antigen which, in its native state is present at the site of secondary neuronal degeneration, is substituted for Copolymer 1 in those indications, it would also work.

With respect to the additional experimentation with Copolymer 1, see also Angelov et al, <u>PNAS</u> 100:4790-4795 (2003) that relates to the treatment of secondary degeneration following facial nerve injury (which is a PNS condition), Kipnis et al, <u>J Neurotrauma</u> 20:559-569 (2003) with respect to the treatment of neurodegeneration following closed head injury, and Schori et al, <u>PNAS</u> 98:3398-3403 (2001) with respect to treatment of secondary neurodegeneration following glutamate toxicity. The examiner's attention is also invited

to WO 03/047500, related to the treatment of secondary degeneration following motor neuron diseases. Another provisional application, 60/518,627, has data relating to the treatment of secondary neurodegeneration following Huntington's disease. This disclosure has been incorporated into a PCT application that has been published as WO 2005/046719, which also has data relating to the treatment of secondary neurodegeneration following Parkinson's disease. Copies of the publications discussed above that are not already of record are attached hereto. All of this evidence confirms applicant's position that the enablement of the present specification would be sufficient to convince those of ordinary skill in the art that the present application would be generally applicable to secondary degeneration following either acute injury or chronic neurodegenerative disease, and therefore that the present claims are indeed commensurate in scope with the enabling disclosure.

In the interview, the examiners stated that a greater amount of evidence of enablement is necessary for a recitation of a specific disease, and so the examiners suggested the deletion of claims such as claims 6, 8, 14 and 16. Accordingly, these dependent claims have now been deleted in view of the potential allowability of the claims from which they depend. This deletion should not be considered as any kind of concession with respect to enablement with respect thereto, and thus the deletion is made without dedication, disclaimer, abandonment, waiver, forfeiture or estoppel. The

examiner's position that the treatment of these specific conditions is not supported by the present specification is duly noted, however, but is obviated by the deletion of these claims.

While the discussion at the interview was directed to the preamble language "a method for reducing secondary neuronal degeneration that follows neuronal damage caused by injury or disease", the presently proposed claims expand "injury or disease" to read "an injury, disease, disorder, or condition". This is being done merely to avoid any confusion as to whether a given indication is truly "a disease". The term "disorder" is supported by the present specification, as it appears, for example, at page 2, line 23; page 37, line 24; page 49, line 17; and page 50, line 15. The term "condition" is supported in the present specification, as it is used, for example, at page 6, line 17; page 38, line 2; and page 59, lines 1, 3, 9 and 11. Accordingly, this language is supported by the specification and should also be permitted.

Another change from the claim language discussed at the interview is in the penultimate administering step of claims 1 and 9. Besides the NS-specific antigen or an immunogenic or cryptic epitope thereof, whose entry and allowability was already agreed to at the interview, the claim has been modified to insert "(iii) a modification of (i) that is immunogenic but not encephalogenic." The present specification clearly states in paragraph [0109] on page 45 that the modification of one or more amino acids at the T cell

receptor binding site is for the purpose of causing the modified peptide to still bind to the T cell receptor such as to be immunogenic, but not encephalitogenic. The subject matter of new claims 50 and 51 are also supported by this paragraph of the specification. Furthermore, new claims 48 and 49 have been added that are specifically directed to the embodiment of treatment of spinal cord injury, as is supported in the present specification, for example, at paragraph [0118] on page 49 of the specification, particularly line 10 of that paragraph.

The examiner has stated that any references that the applicant wishes for the examiner to review and make of record must be supplied in the form of an Information Disclosure Statement pursuant to 37 C.F.R. §1.98(a)(1). It is respectfully submitted, however, that 37 C.F.R. §1.98(a)(1) applies only to Information Disclosure Statements filed under 37 C.F.R. §1.97 and 37 C.F.R. §1.97 and §1.98 only relate to applicant's duty to disclose information material to patentability under 37 C.F.R. §1.56. The references submitted in the previous response in the parent case and those attached hereto are not being submitted as prior art, as they do not necessarily have dates prior to the effective filing date of the present application. They are all being submitted as evidence supporting applicant's position with respect to the enablement rejection, and proving the broad operability of the present invention. Applicants do not require that these documents be listed on the face of the patent, as they are not

In re of Appln. No. 10/810,653
Preliminary Amendment dated March 2, 2006

prior art that is material to patentability. It is sufficient that reference thereto remain in the file history. Applicants are not aware of any rule that states that evidence submitted to support applicants' position with respect to enablement cannot be considered unless submitted on an Information Disclosure Statement pursuant to 37 C.F.R. §1.98(a)(1).

For all of the above reasons, and in view of the amended language of the claims and the additional evidence presented herewith, the present enablement rejection has now been overcome. Reconsideration and withdrawal thereof is therefore respectfully urged.

The present amendment amends the claims substantially in the manner discussed at the interview, and submits the additional information requested by the examiners. Accordingly, it is believed that this amendment places the case into condition for allowance. It is submitted that all of the claims now present in the case clearly define over the references of record and fully comply with 35 U.S.C. §112. Prompt consideration and allowance are therefore earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

Βv

Roger L. Browdy

Registration No. 25,618

our of

RLB:rd

Telephone No.: (202) 628-5197 Facsimile No.: (202) 737-3528 G:\BN\B\BENA\EIS-SCHWARTZ2B\PTO\AmendmentA.doc

300 S	3 1 2000 1 Soriginal	Substitute	Atty. Docket: EIS-SCHWARTZ=2A
Coê	hined Declaration fo	or Patent App	Atty. Docket: EIS-SCHWARTZ=2A
As a below-named i My residence, post	nventor. I hereby declare that: office address and citizenship	are as stated below	next to my name; and that I believe I am the original, first st and joint inventor (if plural names are listed below) of the
	i. : laimage and for Chica it Di	nen is sought on m	
ACTIVATED I CI	I.LS, NERVOUS SYSTEM-S	PECIFIC ANTIGE	NS AND THEIR USES
the specification of			
[is attached hereto: was filed in the United State	es under 35 U.S.C. §	111 on <u>June 28, 2001</u> , as
1.1	U.S. Appln Nowas/will be filed in the U.S.		371 by entry into the U.S. national stage of an international
, ,	(PCT) application. PCT/	: filed	entry requested on*: No*: §371/\$102(e) date*
	(* if known)		
. Lumi amandad	,		(if applicable). nd 34 if PCT)
and was amended ((include dates of amendmen	is under PCT Art. 19 a	nd 34 if PCT) ied specification, including the claims, as amended by any set to the Patent and Trademark Office (PTO) all information
known by me to be	e material to patentability as de eign priority benefits under 35 t breeder's rights certificate(s)	inica in 57 ca ac. y	(d) and 365 (b) of any prior foreign application(s) for patent. of any PCT application which designated at least one country
	Application No.	Country	Filing Date (MM/DD/YYYY) 05/19/1998
	124500	Israel	0.3177.70
If I claimed forei application design date before that o	gn priority above. I hereby id nating a country other than th f the earliest application from v Non-Priority Application No.	entify below any fo c United States) or which foreign priorit Country	reign application for patent (including an international (PCT) for an inventor's or plant breeder's certificate, having a filing y is claimed (if left blank, then there are none): Filing Date (MM/DD/YYYY)
I hereby claim the	e benefit under 35 U.S.C. §119	(e) of any United St	ates provisional applications listed below:
	Application PCT/US98	on No.	Filing Date (MM/DD/YYYY) 07/21/1998
PCT internations application is no	al application(s) designating in of disclosed in such U.S. or P acknowledge the duty to discl- tich became available between	CT international ap	non-provisional application(s) or under §365(c) of any prior and, insofar as the subject matter of each of the claims of this plication in the manner provided by the first paragraph of 35 information which is material to patentability as defined in 37 e prior application and the national or PCT international filing

	Filing Date (MM/DD/YYYY)	Status (patented, pending, abandoned)		
Application No.	05/19/1999	Pending		
09/314.161		Pending		
09/218.277	12/22/1998			

As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with Customer Number 001444, which is presently:

BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197

Page 2 of 2 Pages			CHWARTZ=2A
THE CONTROL CHARGE CHARGES NERVOUS SYSTEM-S	PECIFIC ANTIGENS AND THE	R USES	
	Serial INO.	_	
PCT Application filed	, Seriai No	_	
The undersigned hereby authorizes the U.S. Attorneys of Ben-Ami & Associates as to any action to be taken in the direct communication between the U.S. Attorneys or Ag whom instructions may be taken, the U.S. Attorneys or Africa I hereby further declare that all statements made herein of	ents and the undersigned. In the gents appointed herein will be so r	event of a chang notified by the uno	e of the persons from dersigned. made on information
I hereby further declare that all statements made herein of and belief are believed to be true; and that these statemen so made are punishable by fine or imprisonment, or be jeopardize the validity of the application or any patent iss	oth, under 18 U.S.C. §1001 and	that willful false s that such willful	tatements and the like false statements may
FULL NAME OF FIRST INVENTOR	INVENTOR'S SIGNATURE	,	DATE
Michal EISENBACH-SCHWARTZ	1		16,10-1001
RESIDENCE		CITIZENSHIP	,
		Israeli	
Rehovot, Israel POST OFFICE ADDRESS			
5 Rupin Street, Rehovot 76353, ISRAEL	INVENTOR'S SIGNATURE		DATE
FULL NAME OF SECOND JOINT INVENTOR	Ehris Howbern. [1]	ハン ひっん	16.17.71
Ehud HAUBEN	TE HOUSE PROJECT OF	CITIZENSHIP	
RESIDENCE		Israeli	
Rehovot, Israel		15740	
POST OFFICE ADDRESS	26 P. 1 26 NIO ISPAEL		
c/o The Weizmann Institute of Science; P.O. Box	26; Kenovoj 76100, ISKALL		DATE
FULL NAME OF THIRD JOINT INVENTOR	INVENTOR'S SIGNATURE	_	1/1/2/2/
Irun R. COHEN			1/6/19/07
RESIDENCE		CITIZENSIIIP	` '
Rehovot, Israel		Israeli	
POST OFFICE ADDRESS			
11 Hankin Street, Rehovot, Israel			·
FULL NAME OF FOURTH JOINT INVENTOR	INVENTOR'S SIGNATURE		DATE
Pierre BESERMAN			
RESIDENCE		CITIZENSHIP	
Moshav Sitriya, Israel		Israeli	
POST OFFICE ADDRESS			
Moshav Sitriya 76834, Israel			
	INVENTOR'S SIGNATURE		DATE
FULL NAME OF FIFTH JOINT INVENTOR			
Alon MONSONEGO		CITIZENSHIP	
RESIDENCE		Israeli	
		1.07	
POST OFFICE ADDRESS			
FULL NAME OF SIXTH JOINT INVENTOR	INVENTOR'S SIGNATURE		DATE
Gila MOALEM			<u> </u>
RESIDENCE		CITIZENSHIP	
Rehovot, Israel		Israeli	
POST OFFICE ADDRESS			
FVOI VEEK, ADDITION			

ALL INVESTORS MUST REVIEW APPLICATION AND DECLARATION BEFORE SIGNING. ALL ALTERATIONS MUST BE INITIALED AND DATED BY ALL INVESTORS PRIOR TO EXECUTION. NO ALTERATIONS CAN BE MADE AFTER THE DECLARATION IS SIGNED. ALL PAGES OF DECLARATION MUST BE SEEN BY ALL INVESTORS.

27 Bosel Street, Rehovot, Israel 76405

Atty. Docket: EIS-SCHWARTZ=2A [X] Original [] Substitute OCI 3 1 2001 Page 1 of 2 Pages Combined Declaration for Patent Application and Power of Attorney As a below-named inventor, I hereby declare that: My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled ACTIVATED T CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS AND THEIR USES the specification of which (check one) is attached hereto; was filed in the United States under 35 U.S.C. §111 on June 28. 2001 (X) was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international filed ز (PCT) application, PCT/_ +; 8371/8102(c) date national stage application received U.S. Appln. No. (* if known) (if applicable). and was amended on (include dates of amendments under PCT Art. 19 and 34 (FPCT) I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information known by me to be material to patentability as defined in 37 C.F.R. § 1.56. I hereby claim foreign priority benefits under 35 U.S.C. §§ 119 (a)-(d) and 365 (b) of any prior foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or under §365(a) of any PCT application which designated at least one country other than the U.S., listed below: Filing Date (MM/DD/YYYY) Country Application No. 05/19/1998 Israel 124500 If I claimed foreign priority above, I hereby identify below any foreign application for patent (including an international (PCI) application designating a country other than the United States) or for an inventor's or plant breader's certificate, having a filing date before that of the earliest application from which foreign priority is claimed (if left blank, then there are none): Filing Date (MM/DD/YYYY) Non-Priority Application No. I hereby claim the benefit under 35 U.S.C. §119(c) of any United States provisional applications listed below: Filing Date (MM/DD/YYYY) Application No. 07/21/1998 PCT/US98/14715

I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or under §365(c) of any prior PCT international application(s) designating the U.S., listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 C.F.R. \$1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Status (patented, pending, abandoned) Filing Date (MM/DD/YYYY) Application No. Pending 05/19/1999 09/314,161 Pending 12/22/1998

As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with Customer Number 001444, which is presently:

BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197

					-n-7A
	Lun Pro	tot: El	is-schiw.	ARI	Z-Z-
	ANY, DO	888			
CFICAN	TOENS AND IDEAS				
Serial No	0				
Soriel No	4	17	- (minis	Joos	from Webb
	wind bereit to poor	EDG TOIN	no this sp	o Box	TOT WILLIAM
Agents Aft	on Trademark Office	wat of s	क्षाम्	the y	emon non
D'R' Lan	understoned to the or	dilled by	y the critical	AL PROPERTY	7 1.
PORT SOUTH	inted barein will be at a		A AL ME	tons	sits made on
94	Laurentedan ME Tre	90 200 1	TOTAL MIT	that	William Error
sin of my	CAL MAR BURGE A	ACT THE	2700J 80	d for	4 arigh Mrimm
er there a	money as both under t	8 0 200	. •		
OS MENTAL	IN DESCRIPT PROPER SPECIAL			-	
			10	ATE	1
	N'S DOLATURE		1		
DIABALL			VICTOR .		1
1		CHAR	:		
	·	Market	<u> </u>		{
•	1			DAT	В
	TO STONATURE		}		
DIVEN	Die a				
					أسسا
_	·	TER	elli .	_	
-4 5	76100, ISRAE	۵.		T BV	NE S
Box 25, K	- IN STREATURE			\-	
DIA	B(LOR 9 sternes				
		,			
			reell		
		_			
	. •		-	7	DATE
	THE PERSON AND THE		2	. 1	B210.01
\ o	SEPCION & SPORT				
		7	THEFT		
•		_11	Brack!		
				_	DATE
	TO THE PARTY OF				1
	UNENLOS, & PERMANEN				
			क्षां क्षां क्षां	17	
		_]	Israeli	_	
				_	DATE
		arana ma			I was
		-			
-	INVENTOR'S SURGETURE				
	DIVENTOR'S STREET		COMO	200	
	DANDLOS, 2 STREET			307 	
	DANDLON, S STREET		[aracti	3307 	
			Israeli		
			Israeli		
	DEADLOS & STREET		Israeli		T DAVIDANCE LATER A
	Agrain spill U.S. Paice in said the said the said the said the said spirls spir	Serial No. Serial No. Agents suppointed barein to accept U.S. Patern and Trademark Office and and the undersigned. In the series appearance harein will be so used a suppointed harein will be so used these statements, were unade to improve made a improvement, or both, under the improvement, or both, under the improvement, or both, under the improvement is successful the control of the control o	Serial No. Serial No. Serial No. Serial No. Serial No. Agents appointed herein to accept and fall. U.S. Patent and Trademark Office respect to and the undersigned. In the overit of a min and the undersigned. In the overit of a min of my own knowledge are true and to these statements were made with the or imprisonment, as both, under 18 U.S.C. DIVENTOR'S MONATURE DIVENTOR'S MONATURE BOX 26; Rednown 76100, ISRAM. DIVENTOR'S MONATURE GENERAL DIVENTOR'S MONATURE	Serial No. Serial No. Serial No. Serial No. Agents appointed berein to accept and follow instance. U.S. Patent and Trademark Office respecting this applies and the undersigned. In the event of a change of the substance of the serial near appointed berein will be so unified by the cruise in of my own knowledge are tree and that all size it these substances; were made with the instances or imprisonment, were made with the instances or imprisonment, were made with the instances or imprisonment, were made with the instances or imprisonment; were made with the instance or imprisonment; were made to the instance or imprisonment; as both, under 18 U.S.C. \$1001 and the imprison or my patent issued fiscance. Developer's succenture Consensation Serection Developer's succenture Consensation Instance Insta	Agrain appointed barrin to notifice regarding this applies U.S. Petern and Trademan's Office regarding this applies and and the undersigned. In the orbit of a change of the p and and the undersigned. In the orbit of a change of the p and of my own knowledge are tree and that all statements were made with the knowledge that at these statements were made with the knowledge that at inquisomment, or both under 18 U.S.C. \$1001 and the attended or my pattent issued fraction. DATE DATE DATE DATE DATE DATE DATE BOX 26: Rednown 76100, ISRAKL DATE BOX 26: Rednown 76100, ISRAKL DATE GREENERS GREENERS GREENERS GREENERS ISRAEL GREENERS GREENE

ALL UNVERTIONS SIDES BY THE APPLICATION AND DECLERATION SECURED. ALL PLANSACION MEST IS USED BY ALL DEPOSITION.
RO ALTREFUNDO CON IN MADE AFTER THE DECLERATION AS ROSCO. ALL PLANS OF DECLERATION MEST IS USED BY ALL DEPOSITION.

•		1	A DETERMINATION A
	ci Original	Substitute OCT 3 1 20	Atty. Docket: EIS-SCHWARTZ=2A
Page 1 of 2 Pages D	.,	- \2 - K-04	and Power of Attorney
Combined I	eclaration for	Patent Applican	of and Power of Attorney
(Januarium Ti	hereby declare that:		first
19 B DCIDW-Marined in 15the additi	cess and citizenship a	re as stated below next to	my name; and that I believe I am the object of the just inventor (if plural names are listed below) of the on entitled
My residence, post office and	name is listed below)	or an original, first and jo	ion entitled
nd sole inventor (if only one ubject matter which is claimer	d and for which a pate	ent is sought on the invent	TUDID LISES
ubject matter which is claimed CTIVATED T CELLS, NER	VOUS SYSTEM-SP	ECIFIC ANTIGENS AND	THEIR GODG
he specification of which (che	sck ons)		
he specification of which	ed hereto;		T 29 2001 . 88
• • • • • • • • • • • • • • • • • • • •	4 L AL TIMIEND STOTES	under 35 U.S.C. §111 on	Une 28. 248X
[] was/will	be filed in the U.S.	under 35 U.S.C. 83/1 by	entry requested on
(PCT) a	pplication, PCI/	ined II S. Apple. No.	*; §371/§102(c) datc
national	stage application reco	ciam ore tables and	entry into the U.S. national stage of all distances of the control
(* if kn	own		(if applicable).
nd was amended on		man BCT (r) 19 and 34 M	PCD
(includ	e dates of amendments t	under PCT Art. 19 and 34 V	diffication, including the claims, as amended by any patent and Trademark Office (PTO) all information
a a a a a a madarret	and the contents of	the above-identified spec	diffication, including the claims, as antenned by the Patent and Trademark Office (PTO) all information
have reviewed and unders	and I acknowledge	the duty to disclose to the	Papert and Transmiss
amendment referred to above known by me to be material to	patentability as defin	ned in 37 C.F.R. \$1.30.	tination(e) for natent
KINWE BY ZEE OF THE		7 S.C. 88 119 (a)-(d) and	365 (b) of any prior foreign application(s) for patent, CT application which designated at least one country
I hereby claim foreign priorit	y benefits more 35 c	r under \$365(a) of any P	365 (b) of any prior foreign application of country or application which designated at least one country
Implementario AT DIRTE DICEULI 3	TIEMPO DOLUMENTO	•	
other than the U.S., listed bal	u da No	Country	Filing Date (MM/DD/YYYY)
App	lication No. 124500	Israel	05/19/1998
		is. below my foreign an	plication for patent (including an international (PCT) eventor's or plant breeder's certificate, having a filing of the blank then there are none):
If I claimed foreign priority	above, I hereby iden	linited States) of for an i	eventor's or plant breeder's cornicate, naving a rinner
application designating a co	untry other than the	ich foreign priority is clair	plication for patent (including an international trans- poventor's or plant breeder's certificate, having a filing med (if left blank, then there are none):
date before mar or me entre	. oppus	Country	nventor's or plant breeded's extentions of the med (if left blank, then there are none): Piling Date (MM/DD/YYYY)
Non-Prior	ity Application No.	Commy	
			
		A I Tolerad Contac Titol	visional applications listed below: Date (MM/DD/YYYY)
I hereby claim the benefit un	der 35 U.S.C. §119(c)	OI SEA CHICA Grace had	Date (MM/DD/YYYY)
	Application.	140.	07/21/1998
	PCT/US98/14		Augusa
			2265(A) of env trior
		of any prior U.S. non-pr	rovisional application(s) or under \$365(c) of any prior softe as the subject matter of each of the claims of this in the manner provided by the first paragraph of 35 in the manner provided by the first paragraph of 35 in the manner provided by the first paragraph of 35 in the paragraph of 37 in this is presented in 37
I hereby claim the benefit to	m(a) designating the	U.S., listed below and, in:	sofar as the subject blanch of January Branch of 35
bCL furcingrious sphires	May a star on DC	r international application	in the matther provides a defined in 37
application is not disclosed	e the duty to disclose	to the PTO all informat	in the manner provided by the thirt particular in 37 ion which is material to patentability as defined in 37 pplication and the national or PCT international filing
CER \$1.56 which became	available between th	e filing date of the prior a	The course and and a second
date of this application:			Status (patented, pending, abandoned)
Application N	lo. Fil	ing Date (MM/DD/YYYY)	Pending
09/314,161		05/19/1999	Pending
09/314,101		12/22/1998	Pending

As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with Customer Number 001444, which is presently:

BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197

Page 2 of 2 Pages	Att	y. Docket: KIS	-schwartz=2
Title: ACTIVATED T CELLS. NERVOUS SYSTEM-	SPECIFIC AND THEIR	USES	
U.S. Application filed June 28, 2001	Serial No.		
PCT Application filed	, Senai No		
The undersigned hereby authorizes the U.S. Attorn Webh Ren-Aml & Associates as to any action to be twithout direct communication between the U.S. Att persons from whom instructions may be taken, the undersigned.	taken in the U.S. Patent and Trade orneys or Agents and the undersi c U.S. Attorneys or Agents appoin	smark Office regi igned. In the ev nted herein will	rent of a change (be so notified b
i hereby further declare that all statements made be information and belief are believed to be true; and statements and the like so made are punishable by willful false statements may jeopardize the validity	i that these statements were made y fine or imprisonment, or both.	under 18 U.S.C.	COLD COLD WILLIAM
FULL NAME OF FIRST INVENTOR	INVENTOR'S SIGNATURE		DATE
Michel BISENBACH-SCHWARTZ		CTUZENSHIP	
RESIDENCE		Israeli	
Rehovot, Israel		1 marit	
POST OFFICE ADDRESS			
5 Rupin Street, Rehovot 76353, ISRAEL			T
FULL NAME OF RECOND FOINT INVENTOR	INVENTOR'S SIGNATURE		DATE
Bhud HAUBEN			<u> </u>
DESIDENCE		Israeli	
Rehovot, Israel		TREACT	
POST OFFICE ADDRESS	TOP A DECLARATION AND A DE		
c/o The Weizmann Institute of Science; P.O. B	ox 20; Redovot 70100, ISRAEL		DATE
FULL NAME OF THIRD JOINT DIVENTOR	INVENTOR'S STENATURE		IMIN .
Irun R. COHEN		CHTERNETIP	<u> </u>
REZIDENCE		Igraeli	
Rehovot, Israel		TRIBBU	
POST OFFICE ADDRESS			
11 Hankin Street, Rehovot, Israel	·		75.
FULL NAME OF FOURTR JOINT INVENTOR	INVENTOR'S SIGNATURE	•	DATE
Piece BESERMAN		T	
RESUMENCE CTU ZEVIEHIP			
Moshav Sitriya, Israel		Israeli	
POST OFFICE ADDRESS			
Moshav Sitriya 76834, Israel			13.55
FULL NAME OF FIFTH JOINT INVENTOR	INVENTOR'S SIGNATURE		Oct. 16.01
Alon MONSONEGO	li C	T designation	100.100
Robovet ISRAEL	,	CITIZENSHIP Izraeli	
rost office aposess Kelar Hanoar Ben-S	Lomon 73112	(Ben-	Yosef)
	INVENTOR'S SIGNATURE		DATE
FULL NAME OF SOUTH POINT INVENTOR	MADAINE B DIEGAST CHEE		
Gila MOALEM		CITZENSED	
RESIDENCE Release Templ		Israchi	-00
Rchovot, Israel POST OFFICE ADDRESS			
27 Rosel Street, Rehovot, Israel 76405			
A I DURCE OFFICE DESIGNATION TO TAKE A CARD			

ALL IMPORTORS MUST REVIEW APPLICATION AND DECLARATION BENGE ECONOL. ALL ALTERATIONS MUST BE DETIRATED AND PATED BY ALL INVIDITORS MUST TO EXCEPTION. NO ALTERATIONS CAN BE MADE AFTER THE RECEIVED AND PATED BY ALL INVIDITORS MUST BE EXCENTED.

Page 1 of 2 Pages [X] Original [] Substitute Atty. Docket: EIS-SCHWARTZ=2A

Combined Declaration for Patent Application and Power of Attorney

	med Decimination			
As a below-named in	ventor. I hereby declare that	:	and that I believe I am the original, first	
Wa B DEIOM-Hornog to	ffice address and citizenship	arc as stated below next to	o my name; and that I believe I am the original, first oint inventor (if plural names are listed below) of the ion entitled	
end sole inventor (if	only one name is listed belo	w) or an original, first and)	fon entitled	
subject matter which	only one name is listed belo is claimed and for which a p	atent is sought on the model	THEIR USES	
ACTIVATED T CEL	is claimed and for which a p LS NERVOUS SYSTEM-	SECULO WILLDENS 1871	7.3.3.3.4	
the specification of w	hich (check one)			
[]	is attached hereto;		June 28. 2001 88	
įxj	was filed in the United Stat	es under 33 U.S.C., grii uz	international	
	U.S. Appln. No.	mder 35 U.S.C. \$371 by	entry into the U.S. national stage of an international entry requested on	
[]	OCT application PCT/_	filed	entry requested on	
	national stage application I	eceived U.S. Appln. No	entry into the U.S. nanonal stage of all distributions, entry requested on	
	(* if known)	•	(if applicable).	
and was amended on		707 (v. 10 md 34 N	PCT)	
WIND AND SHOTTON	(include dates of amendment	is under PCT Art. 19 and 34 V	or an alaims or emended by BDY	
amendment reterred	to souve, and a second	Ened in 37 C.F.R. 81.56.	cification, including the claims, as amended by any a Patent and Trademark Office (PTO) all information	
I hereby claim forci	gn priority benefits under 3:	5 U.S.C. §§ 119 (a)-(d) and or under §365(a) of any P	365 (b) of any prior foreign application(s) for patent, CT application which designated at least one country	
other than the U.S.,	31 COCO 2 2 1 Prom 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4			
Other man me elect	Application No.	Country	Filing Date (MM/DD/YYYY)	
	124500	Israel	05/19/1998	
application designa data before that of t	ting a country other than the earliest application from the Priority Application No.	e United States) of for an a which forcign priority is clai Country	plication for patent (including an international (PCT) aventor's or plant breeder's certificate, having a filing med (if left blank, then there are none): Filing Date (MM/DD/YYYY)	
				•
		(c) of any United States pro	visional applications listed below: Date (MM/DD/YYYY)	
I hereby claim the	enetit under 35 U.S.C. \$113	Filias	Date (MM/DD/YYYY)	
	Application PCT/US98	AL 2.1-	07/21/1998	
•				
PCT international	disclosed in such U.S. or P mowledge the duty to disclo	CT international application	rovisional application(s) or under §365(c) of any prior sofar as the subject matter of each of the claims of this in the manner provided by the first paragraph of 35 ion which is material to patentability as defined in 37 pplication and the national or PCT international filing	
		Filing Date (MM/DD/YYYY)	Status (patented, pending, abandoned)	
	Illeanon No.	05/19/1999	Pending	
	9/314,161	12/2/100f	Pending	
As a named inver	stor, I hereby appoint the f	following registered practiti	oners to prosecute this application and to transact all	
business in the Pat	ent and Trademark Office co	itioners associated with Cu	stomer Number 001444	
	All of the pract	ated with Customer Number	on 1444, which is presently:	
Direct all correspo	Doence to the somess associ	BROWDY AND NEIM	ARK, P.L.L.C.	
		DISCOTTO S INCIDENT		

BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197

THE ACTIVATED T CHILS NERVOUS SYSTEM-SPECIFIC ANTIGENS AND THEIR L	dea: e18-schwartz- ises
THE ACTIVATED T CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS AND THRIP I	1989
. U.S. Application filed June 28, 2001 Serial No.	
PCT Application filed Serial No.	
The ordersigned hereby authorizes the U.S. Attorneys or Agenty appointed herein to accept a	not reliablished would be
The first the second section as the section of the first three to the first three three to the first three to the first three to the first three three to the first three three to the first three th	PROPERTY IN LINE BUYER SHOWS
direct communication between the U.S. Attorneys or Assemb and the understand. In the even	Lik Ok a guimfac at Als bearin
whom instructions may be within the U.S. American or Agents appointed havels will be so notifi	test by ethe ettroughtern.
I hereby further declare that all statements made berein of my awa knowledge are true and that	oil matements made on info
and half of our half and in he torrer and they there protection with the knowledge that I	
so medic are numberable by fine or imprisonment of both, under 18 U.S.C. (100) and that	such within the spices
isobauges the religion of the adoptionion of and beautiful process.	•
	•
MULHANE OF FIRST DIVENTOR PROPERTY BEIGNATURE	DATE .
	. [
Michai Eisenbach-schwartz	
	SEPTEMP.
Rehavot, Israel Israel	6611
POST DYFICE ADDRESS	
5 Rupin Street, Rehovot 76353, LERABL	•
FUEL NAME OF SECOND SCIENT DIVENTOR'S DOWNTURE	DATE
Elmid HAUSEN	
	Z96H7
Rehavot, Irrael len	1531
2087 DEFICE ADDRESS	• •
of The Weismann Institute of Science; P.O. Box 26; Rehovet 76100, INRAEL	
FULL NAME OF THURD JOINT INVESTOR DAVISITOR'S SUPERIORE	DATE
Iron R. COHEN	
RESIDENCE . CITY	ZENEIGE
Rehovet, Israel	agli •
POST OFFICE ACCRESS	
11 Hankin Street, Rehovet, Israel	
PLAT HAVE OF FOURTH FORT INVENTOR DIVENTOR & REPLATURE	SATE
Plane BRSERMAN	
ALEMBICE CIT	ZENSPÜ
Kilbhutz Chafese Chairn, Israel	eli'
POST OFFICE ADDITION	•
Kibbutz Chafetz Chaim 76817, Israel	•
PULL NAME OF REPORTORY DAY BY 100: OF THE POPULATION OF THE POPULATION	DATE
Alon MONSONEGO	
1	ZIENOSIIP
Ibra	eli '
POST CAFACE ADORESS	•
	•• • • • • • • • • • • • • • • • • • • •
PULL NAME OF EXCEPTION INVENTOR . DIVESTOR'S EXCEPTION	DATE
mu	
	C Odoby 13
	CO ISPACIO
L. Th Between formal	ðli 💮
S HAVE PARTY OF THE PARTY OF TH	
POST CIPICE ADDRESS. ST BOOM STORE RESIDENCE COMES 31 Orley Street Real-	iova 49942

WIT EMPLOYED WITH SEALER, That Sulfaction from designation designed with the product of interpretable from SE Sulfaces and Dividio SA wit substitutes and dividio sa sulfaces and dividio sa substitutes and dividio sa sulfaces and dividio sa sulfaces and sulfaces and

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
□ other:

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.